Table 1

Gp96-therapy of metastatic disease.

Start of treatment post-tumor challenge (day) Disease-incidence in mice treated with
Buffer D122-gp96 Liver-gp96
29 89% (8/9) 0% (0/10) 44% (4/9)
31 100% (10/10) 0% (0/10) 55% (5/9)
33 100% (9/9) 40% (4/10) 100% (9/9)